Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
7.9
USD
|
+4.91%
|
|
+1.54%
|
+0.25%
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
42.07
|
91.57
|
380.5
|
275.9
|
57.51
|
184.9
|
-
|
-
|
Enterprise Value (EV)
1 |
42.07
|
91.57
|
380.5
|
275.9
|
57.51
|
184.9
|
184.9
|
184.9
|
P/E ratio
|
-0.75
x
|
-1.07
x
|
-6.2
x
|
-3.94
x
|
-0.92
x
|
-1.41
x
|
-3.54
x
|
-8.88
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.16
x
|
-
|
-
|
-
|
-
|
-
|
19.3
x
|
3.02
x
|
EV / Revenue
|
5.16
x
|
-
|
-
|
-
|
-
|
-
|
19.3
x
|
3.02
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-1,285,407
x
|
-
|
-
|
-4,868,083
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-3.92
x
|
-
|
71.9
x
|
29.6
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,412
|
6,359
|
8,767
|
11,307
|
13,012
|
23,406
|
-
|
-
|
Reference price
2 |
29.80
|
14.40
|
43.40
|
24.40
|
4.420
|
7.900
|
7.900
|
7.900
|
Announcement Date
|
12/19/19
|
12/23/20
|
12/22/21
|
12/29/22
|
12/22/23
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
8.146
|
-
|
-
|
-
|
-
|
-
|
9.569
|
61.13
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-36.3
|
-36.84
|
-51.73
|
-63.07
|
-53.13
|
-66.96
|
-61.7
|
-25.27
|
Operating Margin
|
-445.6%
|
-
|
-
|
-
|
-
|
-
|
-644.79%
|
-41.33%
|
Earnings before Tax (EBT)
1 |
-37.93
|
-38.51
|
-53.16
|
-66.05
|
-58.98
|
-111.8
|
-66.85
|
-29
|
Net income
1 |
-36.04
|
-48.87
|
-53.16
|
-66.05
|
-58.98
|
-120.9
|
-66.85
|
-28.92
|
Net margin
|
-442.42%
|
-
|
-
|
-
|
-
|
-
|
-698.58%
|
-47.31%
|
EPS
2 |
-39.60
|
-13.40
|
-7.000
|
-6.200
|
-4.800
|
-5.600
|
-2.230
|
-0.8900
|
Free Cash Flow
|
-32.73
|
-
|
-
|
-56.67
|
-
|
-
|
-
|
-
|
FCF margin
|
-401.75%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/19/19
|
12/23/20
|
12/22/21
|
12/29/22
|
12/22/23
|
-
|
-
|
-
|
Fiscal Period: September |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1.65
|
1.95
|
2.25
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.15
|
-18.91
|
-17.02
|
-13.99
|
-15.69
|
-6.838
|
-18.14
|
-12.46
|
-10.32
|
-18.94
|
-18.66
|
-19.23
|
-14
|
-13.7
|
-13.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-848.48%
|
-702.56%
|
-591.11%
|
Earnings before Tax (EBT)
1 |
-14.46
|
-19.7
|
-17.54
|
-14.34
|
-18.66
|
-6.651
|
-20.68
|
-12.99
|
-11.18
|
-114.3
|
-19.09
|
-20.28
|
-16.5
|
-16.2
|
-15.8
|
Net income
1 |
-14.46
|
-19.7
|
-17.54
|
-14.34
|
-18.66
|
-6.654
|
-20.68
|
-12.99
|
-11.18
|
-114.3
|
-19.46
|
-20.37
|
-16.5
|
-16.2
|
-15.8
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,000%
|
-830.77%
|
-702.22%
|
EPS
2 |
-1.600
|
-1.800
|
-1.600
|
-1.200
|
-1.600
|
-0.6000
|
-1.600
|
-1.000
|
-0.8000
|
-8.010
|
-0.8133
|
-0.8267
|
-0.6800
|
-0.6500
|
-0.6200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/14/22
|
5/13/22
|
8/10/22
|
12/29/22
|
2/14/23
|
5/15/23
|
8/14/23
|
12/22/23
|
2/14/24
|
5/15/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-32.7
|
-
|
-
|
-56.7
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-7.600
|
-
|
0.6000
|
0.8200
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.44
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
5.37%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/19/19
|
12/23/20
|
12/22/21
|
12/29/22
|
12/22/23
|
-
|
-
|
-
|
Average target price
38.43
USD Spread / Average Target +386.44% Consensus |
1st Jan change
|
Capi.
|
---|
| +0.25% | 185M | | +67.53% | 63.85B | | -0.77% | 41.83B | | +45.66% | 40.65B | | -10.72% | 27.12B | | +13.30% | 26.52B | | -22.79% | 18.69B | | +4.70% | 12.73B | | +24.10% | 12.11B | | +27.41% | 12.07B |
Other Biotechnology & Medical Research
|